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Abstract
The conception of internal mammary sentinel lymph node biopsy (IM‐SLNB) has been
added to the 2009 American Joint Committee on Cancer breast cancer staging manual.
However, there has still been slight variation in the surgical treatment model owing to
the low visualization rate of internal mammary sentinel lymph nodes (IM‐SLN) with
the traditional radiotracer injection technique. According to the hypothesis of IM‐SLN,
a  modified  injection  technique  (periareolar  intraparenchymal,  high  volume,  and
ultrasound guidance) was established, which could significantly improve the IM‐SLN
visualization rate, and make the IM‐SLNB procedure possible in routine practice. IM‐
SLNB  could  provide  minimally  invasive  staging,  prognosis,  and  decision‐making
individually, especially for the patients with clinically positive axilla lymph nodes.
Moreover, radiotherapy targeting on internal mammary lymph nodes (IMLN) should
be tailored and balanced between the potential benefit and toxicity, and radiotherapy
guided by IM‐SLNB could achieve this goal. In the era of emphasizing the effective
adjuvant therapy, within the changing therapy approach—more systemic treatment,
less loco‐regional treatment—oncologist should reconsider the application of regional
IMLN therapy.
Keywords: breast cancer, internal mammary lymph node, internal mammary sentinel
lymph node biopsy, radiotherapy, lymphatic drainage
1. Introduction
Surgical management of the axilla, however, has undergone a paradigm change since the
concept of lymphatic mapping in breast was introduced at the John Wayne Cancer Institute in
1991, and sentinel lymph node biopsy (SLNB) has replaced axillary lymph node dissection
(ALND) for axillary staging in clinically node‐negative early breast cancer. There is a large
body of evidence showing that SLNB is an accurate staging procedure in expert hands, and it
is now the standard of care for staging clinically node‐negative invasive breast cancer.
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Furthermore, the results of the ACOSOG Z0011 trial indicated that the patients with a positive
axillary sentinel lymph node (ASLN) that may avoid ALND include those with clinical T1–2,
N0 breast cancer with one or two positive ASLN who plan to undergo lumpectomy with whole
breast radiation and systemic therapy. However, the internal mammary sentinel lymph node
biopsy (IM‐SLNB) is far behind that of the axilla for the low visualization rate of internal
mammary sentinel lymph node (IM‐SLN) with the traditional radiotracer injection technique.
Based on the hypothesis that the IM‐SLN receives the lymphatic drainage from not only the
primary tumor area, but also the entire breast organ. The Modified radiotracer injection
technique significantly improved the IM‐SLN visualization rate, making the routine IM‐SLNB
possible in daily practice, and further offer individual management for IMLN. In this article,
the technical matter, indication and clinical significance of IM‐SLNB were discussed, and we
would like to identify the breast cancer patients who may benefit from this minimally invasive
diagnostic technique.
2. The significant of internal mammary lymph node in breast cancer
In addition to the axillary lymph nodes (ALN), the internal mammary lymph nodes (IMLN)
drainage is another first‐echelon nodal drainage site in breast cancer [1]. The status of IMLN
also provides important regional staging and treatment choice information for breast cancer
patients [1, 2]. As reported in the previous studies of extended radical mastectomy, patients
with no ALN/IMLN metastases had a 10‐year overall survival (OS) rate of 82% compared with
54% for only ALN metastases patients, 38% for only IMLN metastases patients, and 17% for
patients with involvement of both nodal, suggesting that regional disease in either nodal chain
has the same prognostic relevance [3–5]. The National Comprehensive Cancer Network
(NCCN) Clinical Practice Guidelines recommend to strongly consider radiotherapy to IMLN
for patients with positive ALN or tumor >5 cm (category 2B), noting “radiotherapy should be
given to the IMLN that are clinically or pathologically positive; otherwise, the treatment to the
IMLN is at the discretion of the treating radiation oncologist” on this topic.
The nodal status of axillary has been well‐established with SLNB and/or ALND in breast cancer
patients. However, regional staging and treatment choice could not be achieved just with the
ALN status, which might cause under‐stage and under‐/over‐treatment. Handley and Thack‐
ray reported that 33% patients had IMLN involvement during survey biopsy, and a back‐up
IMLN dissection was frequently added to the radical mastectomy starting in the 1950s [6–9].
However, this radical surgical procedure was abandoned due to its extra complications, longer
operation time, and lack of survival benefit [10]. Imaging techniques, such as ultrasound, MRI,
and PET/CT, could usually detect metastases lesions larger than 5 mm, but due to the deep
anatomical location and small size of IMLN, the sensitivity of current imaging techniques
cannot satisfy the clinical practice. Therefore, a minimally invasive method is still lacked to
evaluate the status of IMLN, and individual IMLN radiotherapy could not be performed.
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3. Modified injection technique with high visualization rate
The IM‐SLNB provided a less invasive method for assessing IMLN than surgical dissection
(Figure 1) and may affect decision‐making for regional and systemic therapy [11, 12]. Although
the 2009 American Joint Committee on Cancer (AJCC) staging incorporated the IM‐SLNB
concept, there has been little change in surgical practice patterns due to the low visualization
rate of IM‐SLN with the traditional radiotracer injection technique [13, 14]. Several studies
have discovered that superficial injection (intradermal, subdermal, periareolar, and subareo‐
lar) of radiotracer was hard to identify IM‐SLN, while intraparenchymal injection (peritumor‐
al, intratumoral, or subtumoral) was more reliable [15–18]. These results suggest that the
dermal and subdermal lymphatic flow is rarely directed to the internal mammary region, while
some intraparenchymal lymphatic flow is directed to the internal mammary region. Unfortu‐
nately, with the traditional intraparenchymal injection technique, the internal mammary
hotspots were only seen in a small proportion of patients (average 13%, range 0–37%), which
has restricted the clinical studies and daily practice of IM‐SLNB to date (Table 4) [15–20].
Figure 1. Internal mammary sentinel lymph node biopsy. (A1 & A2 is mastectomy, B1 & B2 is lumpectomy.)
Qiu et al. tried injecting radiotracer with a modified technique (periareolar intraparenchymal,
high volume, and ultrasound guidance) and got a high lymphoscintigraphy visualization rate
of IM‐SLN (71.1%, 248/349) (Figure 2) [21, 22]. This might provide a technical feasibility of IM‐
SLNB, therefore, IM‐SLNB could be performed routinely in clinical studies and daily practice
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and might potentially impact treatment decision‐making. However, the basic problem in Qiu's
study is the same as all the previous research, because a back up IMLN dissection have not
been performed following the IM‐SLNB, the accuracy of this minimally invasive technique
have not been verified directly. During the IM‐SLNB studies, the IM‐SLN were concentrated
in the 2nd and 3rd intercostal space, which were consistent with the sites of IMLN metastasis
in the previous studies of IMLN dissection [6, 10]. These results indirectly confirmed accuracy
of IM‐SLNB. However, a backup lMLN dissection should be required to validate accuracy of
IM‐SLNB before its clinical application.
Figure 2. Schematic model of the modified injection techniques.
Additionally, the IM‐SLNB is more difficult than axillary SLNB, with success rates of 70–100%.
Pleural breach and internal mammary vessel bleeding are the most commonly reported
complications from IM‐SLNB, occurring in approximately 5% of patients, although pneumo‐
thorax and significant postoperative morbidity are rare. Several studies reported the change
in clinical management caused by the additional information provided by IM‐SLNB [23–28].
IM‐SLNB leads to more complete regional staging.
4. Validation study for the hypothesis of internal mammary sentinel
lymph node lymphatic drainage in breast cancer
It is generally known that the hypothesis of ASLN lymphatic drainage pattern was proved
with subsequent ALND in the breast cancer [29–31]. However, the hypothesis of IM‐SLN
lymphatic drainage has not been confirmed. As the extended radical mastectomy (included
complete internal mammary chain dissection) has been abandoned since 1960s [4, 32, 33], the
hypothesis of IM‐SLN lymphatic drainage pattern cannot be validated by this way. Now,
another method was used to validate the IM‐SLN lymphatic drainage hypothesis in our
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study. Two different tracers (fluorescence tracer [ICG] and radiotracer [99mTc‐labeled sulfur
colloid]) were injected in different sites of the intra‐parenchyma to observe whether they
could reach to the same IM‐SLN in the breast cancer patient. In the clinical practice, the ICG
fluorescence tracer is a safe and effective method for sentinel lymph node biopsy (SLNB) in
the breast cancer with acceptable sensitivity and specificity comparable to conventional
methods (blue dye and radioisotope) [34–36]. In our breast cancer center, it has been
compared with the combined method (blue dye with radiotracer [99mTc‐labeled sulfur
colloid]) in identifying ASLN. The results showed that all ASLN identified by the combined
method also were the ICG fluorescence positive and the non‐sentinel lymph nodes were the
ICG negative after ALND (n = 69, P < 0.05). The anatomy study of the lymphatics in the breast
found that IMLN commonly receive less than 25% of the total lymphatic drainage from the
breast [37]. Due to little volume of ICG tracer is difficult to detect by the fluorescence imaging
system, it is hard to find IM‐SLN by this tracer in the internal mammary lymph chain. But
IM‐SLN can be detected by radiotracer with the modified radiotracer injection technique and
can be performed biopsy in the internal mammary lymph chain guided by this technique.
In the validation study of the IM‐SLN lymphatic drainage hypothesis, the ICG fluorescence
tracer was injected intraparenchymally guided by breast ultrasound at the peritumoral, the
radiotracer was injected intraparenchymally with the modified radiotracer injection techni‐
que. This method is used to identify different tracers injected in different sites that could
reach to the same IM‐SLN. The radioactive IM‐SLNs were detected by preoperative lym‐
phoscintigraphy (Figure 3) 30 min before the surgery and gamma probe during the surgery.
IM‐SLNB was performed for patients with the radioactive IM‐SLNs. After IM‐SLN removed,
the status of IM‐SLN was identified by intraoperative gamma probe and fluorescence
imaging system (Figure 4). The correlations between the radiotracer and the fluorescence
tracer in the same IM‐SLN were calculated using the Spearman rank correlation coefficient.
The criteria for judging the size of the correlation coefficient were applied: correlations <0.30
are considered minor, correlations between 0.3 and 0.49 are considered medium, and ≥0.5
are considered strong. Cohen's kappa statistic was used to determine inter‐examiner
agreement. According to Altman's guidelines, it is poor when kappa scores ≤0.20, fair when
kappa between 0 and 0.40, moderate when kappa between 0.41 and 0.60, good when kappa
0.61–0.80, and very good when kappa ≥0.80. The results showed that 145 patients underwent
IM‐SLNB successfully and 127 cases of them identified the radiotracer and the fluorescence
tracer reached to the same IM‐SLN, 18 cases were detected only the radiotracer positive IM‐
SLN (Table 1). Accordingly, the radiotracer and the fluorescence tracer in the same IM‐SLN
showed a strong correlation coefficient at 0.836 (Case‐base, rs >0.5, P < 0.05). The degree of
agreement between the radiotracer and the fluorescence tracer was Kappa = 0.823 (very good),
showing high degree of agreement between the two tracers (Kappa > 0.8, P < 0.05). The results
showed that the lymphatic drainage from different location of the breast (the primary tumor,
the subareolar plexus) reached to the same IM‐SLN, which means that IM‐SLN receives
lymphatic drainage from not only the primary tumor area but also the entire breast paren‐
chyma. By this method, the hypothesis of IM‐SLN lymphatic drainage pattern was demon‐
strated [38].
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Figure 3. Preoperation lymphoscintigram with radiotracer. Hotspots are evidently shown in both the second intercos‐
tal space (A) and the fourth intercostal space (B) in patient with left‐sided breast cancer.
Figure 4. Intraoperative IM‐SLNB identified the location of IM‐SLN in the fourth intercostal space. The fluorescence
imaging system showed the IM‐SLN fluorescence tracer positive (B).
Tracers map Radiotracer+ Radiotracer- Total
Fluorescence tracer+ 127 0 127
Fluorescence tracer- 18 71 89
Total 145 71 216
Table 1. Different tracers identified in IM‐SLN.
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Furthermore, the radiotracer was not injected in peritumoral intra‐parenchyma but in
periareolar intra‐parenchyma with the modified technique based on the hypothesis. The
question arises as to whether all nodes detected by the modified technique should be
considered as “true” IM‐SLN or whether some of them are actually “second‐tier” IMLN. The
accuracy of the modified radiotracer injection technique has been confirmed by our team at
the previous study [39]. The results showed that IM‐SLN detected by the modified technique
could reflect the real lymphatic drainage of the whole breast parenchyma. In other words, the
modified technique can detect the “true” sentinel node in the internal mammary chain. Also,
the results of the metastases site and the number of IM‐SLNs were in accordance with the past
study of extended radical mastectomy, which could reflect the accuracy of IM‐SLNB indirectly
[2, 40, 41]. There were no serious adverse events or reactions after the radiotracer injected
guiding by the modified injection technique.
5. IM-SLNB should be performed in clinically ALN-positive patients
Several studies indicated that IM‐SLNB have little clinical relevance because tumor‐positive
IM‐SLN rarely influence adjuvant treatment strategy and did not affect overall survival [11,
13]. We agree with these results but it should be interpreted with caution for the limitation of
their study population. The study population in all current research relate to SLNB (both axilla
and internal mammary) was the patients with clinically negative ALN. Because the IMLN
involvement is mostly found concomitantly with ALN involvement [10], more attention
should be focused on the IM‐SLNB in clinically positive ALN patients. Huang et al. [42]
retrospectively analyzed 2269 Chinese patients who received extended radical mastectomy
and showed that the probability of IMLN metastases was 4.4% for patients with negative ALN,
18.8% for 1–3 positive ALN, 28.1% for 4–6 positive ALN and 41.5% for more than 6 positive
ALN. Veronesi et al. also indicated that the IMLN positive rate increased significantly from
9.1% in negative ALN to 29.1% in positive ALN patients [6]. Qiu reported that the IM‐SLN
positive rate was only 8.1% in clinically negative ALN patient, and adjuvant therapy was
altered in a small proportion. However, the IM‐SLN positive rate was 20.5% in clinically
positive ALN, and individual radiotherapy strategy could be tailored with this IM‐SLNB
result [22]. To summarize, previous IM‐SLNB research failed to assess the IMLN status who
really were in need, we could found the evidence from the above results that the patients with
clinically positive ALN could get more benefit from the IM‐SLNB. Therefore, Qiu et al.
suggested that the IM‐SLNB research should be encouraged in the clinically positive ALN
patients [43].
6. Internal mammary lymph node radiotherapy of breast cancer
For many patients, improvement of systemic therapy will decrease the risk of death due to
distant metastasis, after which the importance of optimized local therapy—which will already
be better after systemic treatment—will, relatively, contribute more to survival [44]. Radio‐
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therapy could reduce local recurrence and improve survival after mastectomy and breast
conserving surgery [45, 46].
The results of Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta‐analysis
showed that one breast cancer death being avoided in the first 15 years after radiotherapy for
every four recurrences of any type (i.e., either loco‐regional or distant) avoided in the 10 years
after radiotherapy for patients with breast conserving surgery. And about one breast cancer
death was avoided in the 20 years after radiotherapy for every 1.5 recurrences of any type (i.e.,
either loco‐regional or distant) avoided during the first 10 years after radiotherapy for patients
with positive lymph node [46].
The meta‐analysis from EBCTCG involved 8135 patients and randomly assigned them to the
chest wall and regional lymph nodes radiotherapy after mastectomy and axillary surgery
versus the same surgery but no radiotherapy. For 1314 patients with 1–3 positive ALN after
ALND, postmastectomy radiotherapy could reduce loco‐regional recurrence (LRR), overall
recurrence (OR, rate ratio [RR] 0.68, 95% confidence interval [CI] 0.57–50.82), and breast cancer
mortality (BCM, RR 0.80, 95% CI 0.67–60.95, all P < 0.05). For patients with systemic therapy
(86.2%, 1133/1314), postmastectomy radiotherapy also could reduce LRR, OR (RR 0.67, 95%
CI 0.55–50.82), and BCM (RR 0.78, 95% CI 0.64–60·94, all P < 0.05). Furthermore, for 1772
patients with ≥4 positive ALN after ALND, radiotherapy also could reduce LRR, OR (RR 0.79,
95% CI 0.69–60.90), and BCM (RR 0.87, 95% CI 0.77–70.99, all P < 0.05). However, the benefit of
postmastectomy radiotherapy might be greater for patients irradiated today because of
radiotherapy planning changing substantially and patients receiving better coverage of target
areas. Today, with the rapid development of the radiotherapy techniques, the doses to normal
tissues would be lower, the risks of radiotherapy would be lower, and the benefits of post‐
mastectomy radiotherapy would be larger than in these trials. However, due to the improve‐
ment of detection and treatment in breast cancer, which makes the absolute risks lower in
breast cancer recurrence and mortality, the absolute benefit of postmastectomy radiotherapy
today would be smaller than in this study [47].
The MA.20 trial from National Cancer Institute Common Clinical Trials Group found that
the addition of regional nodal radiotherapy (including IMLN) to whole‐breast radiotherapy
reduced the rate of breast cancer recurrence in patients with node‐positive or high‐risk node‐
negative breast cancer. A total of 1832 patients were assigned to the nodal‐radiotherapy
group or the control group (916 patients in each group) in this trial. At the 10‐year follow‐
up, the rates of disease‐free survival (DFS) in the nodal‐radiotherapy group was better than
that in the control group (82.0 vs. 77.0%; [HR] 0.76 [95% CI, 0.61–60.94], P = 0.01). But, there
was no significant between group difference in OS, with a rate of 82.8% in the nodal‐
radiotherapy group and 81.8% in the control group (hazard ratio [HR], 0.91; 95% [CI], 0.72
to 1.13; P = 0.38) [48].
In the European Organization for Research and Treatment of Cancer (EORTC) 22922/10925
study, a total of 4004 patients were assigned randomly to the regional nodal radiotherapy
(included IMLN) group or the control group. At a median follow‐up of 10.9 years, the results
showed that regional nodal radiotherapy did not change overall survival (OS) (82.3 vs. 80.7%,
HR 0.87, 95% CI, 0.76–71.00, P = 0.06), but improved DFS (72.1 vs. 69.1%, HR, 0.89, 95% CI,
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0.80–81.00, P = 0.04), the distant metastasis‐free survival (DMFS) (78.0 vs. 75.0%, HR, 0.86, 95%
CI, 0.76–70.98, P = 0.02), and reduced the breast cancer mortality (12.5 vs. 14.4%, HR, 0.82, 95%
CI, 0.70–0.97, P = 0.02) [49].
In the French study, all patients received postoperative radiotherapy to the chest wall and
supraclavicular nodes and were randomly assigned to receive IMLN radiotherapy or not. A
total of 1334 patients were analyzed after a median follow‐up of 11.3 years among the survi‐
vors. No benefit of IMLN radiotherapy on OS could be demonstrated: the 10‐year OS was 59.3%
in the IMLN non‐irradiated group versus 62.6% in the IMLN irradiated group (P = 0.8). The
overestimation of the risk of IMLN involvement (25%) probably decreased the power of the
study [50].
Budach et al. did a meta‐analysis of the MA. 20, EORTC22922/10925, French trials and the
results showed that additional regional radiotherapy to IMLN statistically significantly
improves DFS, DMFS, and OS in stage I–III breast cancer. The absolute benefits in 5‐year OS
were 1.6% in the MA.20 trial, 10‐year OS were 1.6% in the EORTC trial, and 10‐year OS were
3.3% in the French trial (HR 0.88 [95% CI 0.80–0.97], P = 0.012). Regional nodal (the medial
supraclavicular lymph node and IMLN) irradiation (MA.20 and EORTC) was associated with
a significant improvement of DFS (HR 0.85 [95% CI 0.77–0.94]) and DMFS (HR 0.82 [95% CI
0.73–0.92]) [51].
The 2016 NCCN Breast Cancer Clinical Practice Guidelines recommend radiotherapy to IMLN
for patients with ≥4 positive ALN (category 1), and strongly consider radiotherapy to IMLN
for patients with 1–3 positive axillary nodes (category 2A), both after mastectomy and
lumpectomy [52].
The DBCG‐IMN Study initiated by Danish Breast Cancer Cooperative Group, a prospective
population‐based cohort study, found that IMLN radiotherapy increased OS in patients with
early‐stage node‐positive breast cancer. A total of 3089 patients were included in the study,
1492 of them received IMLN radiotherapy and others were no IMLN radiotherapy. With a
median of 8.9 years of follow‐up time, the 8‐year OS rates of IMLN radiotherapy group was
higher than that in the no radiotherapy group (75.9% [95% CI 73.6–78.0] vs. 72.2% [95% CI
69.9–74.4]; [HR] 0.82 [95% CI 0.72–70.94], P = 0.005). Breast cancer mortality in IMLN radio‐
therapy group was lower than that in the no radiotherapy group (20.9% [95% CI 18.8–23.0] vs.
23.4% [95% CI 21.3–25.5]; [HR] 0.85 [95% CI 0.73–70.98], P = 0.03) [53].
In sum, IMLN radiotherapy could reduce loco‐regional and distant recurrence and improve
survival in breast cancer.
7. Internal mammary lymph node radiotherapy guided by internal
mammary sentinel lymph node biopsy
Although the 2016 NCCN Breast Cancer Clinical Practice Guidelines recommend radiotherapy
to IMLN for patients with ≥4 positive ALN, and strongly consider radiotherapy to IMLN for
patients with 1–3 positive axillary nodes, but according to the status of ALN to estimate the
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metastasis risk in IMLN, low‐risk did not mean IMLN negative and high‐risk did not mean
IMLN metastases [54]. Studies of extended radical mastectomy reported that 38.3% (36.8–
46.2%) patients with ≥4 positive ALN, 19.6% (18.8–26.7%) patients with 1–3 positive ALN
identified IMLN metastases, and 9.2% (4.4–16.8%) with negative ALN identified IMLN
metastases. It is obvious that negative IMLN was found in about 60% patients with ≥4 positive
ALN and positive IMLN was found in about 9% patients with negative ALN [33, 42, 55]. Thus,
these inclusion criteria of NCCN Guidelines might induce over‐ and under‐treatment. We
should use a more accurate technique to evaluate the pathology status of IMLN and to guide
IMLN radiotherapy.
The study by Veronesi et al. found that radiotherapy to IMLN will improve the survival
obviously after identifying the metastases by IMLN biopsy. In this clinical study of 68 (10.3%,
68/663) patients receiving radiotherapy to IMLN for histologically proven metastases, radio‐
therapy was highly effective yielded a 5‐year OS of 95% [56].
Currently, IM‐SLNB via intercostal space could make it possible—tailored IMLN radiotherapy
and minimally invasive staging. Even though breast cancer staging has incorporated IM‐SLNB
concept since the 6th edition of AJCC, IM‐SLNB has not been performed routinely [57]. The
studies of IM‐SLNB showed that the success rate of IM‐SLNB has reached 60–100% with
minimal or no changes in operative time, but the visualization rate of IM‐SLN was low [12–
14, 58], which has been the restriction for both clinical study and daily practice of IM‐SLNB.
Now, the modified radiotracer injection technique could improve the IM‐SLN detection rate
from 15.5 to 71% (P < 0.001). Also, the visualization number of IM‐SLN was no difference
between the modified technique group and the traditional tracer injection technique (peritu‐
moral intraparenchymal injection) group in our pilot study (P = 0.692). Up to now, 219 patients
with breast cancer received IM‐SLNB guided by the modified radiotracer injection technique.
The clinically pathological characteristics of the 216 enrolled patients are presented in
Table 2. The detection rate of ASLN was 98.6% (213/216). The overall visualization rate of IM‐
SLN detected by preoperative lymphoscintigraphy and gamma probe was 71.8% (155/216).
96.1% (149/155) of them received IM‐SLNB. The success rate of IM‐SLNB was 97.3% (145/149).
The data on clinical outcome of the patients underwent IM‐SLNB show in Table 3. In 12 patients
underwent breast conserving surgery, 5 cases who were identified the location of primary
tumor could not reach IM‐SLNB had to be made an extra incision in the skin to reach IM‐SLNB.
In patients who performed IM‐SLNB successfully, a total of 279 lymph nodes were removed,
the median number of IM‐SLNs was 2 (range 1–4 nodes). The IM‐SLNs were located in the
first (5.4%, 15/279), second (46.2%, 129/279), third (40.5%, 113/279) and forth (7.9%, 22/279)
intercostal space. All positive IM‐SLNs were in the second (61.1%, 11/18) and the third (38.9%,
7/18) intercostal space. 54.1% (151/279) of IM‐SLN was found in the outside of the internal
mammary vessels and 45.9% (128/279) was in the inside. Details of IM‐SLN mapping and
biopsy are shown in Table 4. The IM‐SLN involvement rate was 8.1% (7/86) in patient with
clinically axillary node negative patients and 18.6% (11/59) in positive patients, respectively.
All patients with positive IM‐SLN received regional nodal radiotherapy to IMLN. The clinical,
pathological, and treatment details of these patients were shown in Table 5. In patients with
≥4 positive axillary lymph nodes, regional nodal radiotherapy to IMLN had been avoided in
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50.0% cases (9/18) with negative IM‐SLN. In patients with 1–3 positive axillary lymph nodes,
regional nodal radiotherapy to IMLN might be avoided in 91.2% cases (52/57) with negative
IM‐SLN.
Characteristic No. %
Age (years)
Median 50
Range 27–79
≤50 119 55.1
>50 97 44.9
BMI
Median 24.1
Range 17.2–33.5
Tumor size
Tis 16 7.4
T1 99 45.8
T2 79 36.6
T3 22 10.2
Tumor location
UOQ 92 42.6
LOQ 25 11.6
UIQ 48 22.2
LIQ 5 2.3
Central 46 21.3
Tumor type
Ductal 187 86.6
Lobular 8 3.7
Mixed 5 2.3
Other 16 7.4
Radiotracer intensity (MBq)
Median 36
Radiotracer volume (mL/point)
Median 0.5
Intervals from injection to SLNB (h)
2–5 89 41.2
16–22 127 58.8
Abbreviations: BMI, body mass index: UOQ, upper outer quadrant; LOQ, lower outer quadrant: UIQ, upper inner
quadrant; LIQ, lower inner quadrant.
Table 2. Descriptive characteristics of eligible patients (N = 216).
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Characteristic No. %
T stage
Tis 9 6.2
T1 70 48.3
T2 57 39.3
T3 9 6.2
N stage
N0 70 48.3
N1 57 39.3
N2 7 4.8
N3 11 7.6
ER
Positive 101 69.7
Negative 44 30.3
PR
Positive 98 67.6
Negative 47 32.4
HER‐2
Positive 44 30.3
Negative 101 69.7
Type of surgery
Lumpectomy + ASLNB 9 6.2
Lumpectomy + ALND 3 2.1
Mastectomy + ASLNB 93 64.1
Mastectomy + ALND 40 27.6
Radiotherapy
WBI 7 4.8
WBI + RNI 5 3.5
PMRT + RNI 79 54.5
No 54 37.2
Chemotherapy
Yes 121 83.4
No 24 16.6
Abbreviations: ER, estrogen receptor status; PR, progesterone receptor status; HER‐2, human epidermal growth factor
receptor‐2; WBI, whole breast irradiation; RNI, regional node irradiation; PMRT, postmastectomy radiotherapy.
Table 3. Clinical outcome of patients who underwent IM‐SLNB (N = 145).
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Characteristic No. %
IM‐SLN map+ 155 71.8 (155/216)
Pt. performed IM‐SLNB 149 96.1 (149/155)
Success rate of IM‐SLNB 145 97.3 (145/149)
Total no. of IM‐SLN 279
Median 2
Range 1–4
IM‐SLN metastatic 18 12.4 (18/145)
IM‐SLNB time (min)
Median 10
Range 3–55
IM‐SLN size (mm)
Median 5
Range 3–12
Table 4. Details of IM‐SLN mapping and biopsy.
No. Tumor
location
T stage No. of
positive
ALN
N stage
without
IM-SLN
No. of
positive
IM-SLN
N stage
with
IM-SLN
Finally stage Chemo-
therapy 
Radio-
therapy
1 UOQ T2 0 pN0 2 pN1b IIA→IIB Yes No→Yes
2 UIQ T2 2 pN1a 1 pN1c IIB (no change)  Yes ? →Yes
3 Central T2 14 pN3a 1 pN3b IIIC (no change) Yes Yes
4 UOQ T2 9 pN2a 1 pN3b IIIA→IIIC Yes Yes
5 UIQ T1c 2 pN1a 1 pN1c IIA (no change)  Yes ? →Yes
6 UOQ T2 1 pN1a 1 pN1c IIB (no change)  Yes ? →Yes
7 UIQ T1a 0 pN0 1 pN1b IA→IIA No→Yes No→Yes
8 UOQ T2 9 pN2a 2 pN3b IIIA→IIIC Yes Yes
9 LIQ T2 5 pN2a 1 pN3b IIIA→IIIC Yes Yes
10 UOQ T1a 3 pN1a 1 pN1c IIA (no change)  Yes ? →Yes
11 UIQ T2 0 pN0 1 pN1b IIA→IIB Yes No→Yes
12 UOQ T3 13 pN3a 1 pN3b IIIC (no change) Yes Yes
13 Central T1c 1 pN1a 1 pN1c IIA (no change)  Yes ? →Yes
14 UOQ T2 13 pN3a 1 pN3b IIIC (no change) Yes Yes
15 Central T2 11 pN3a 1 pN3b IIIC (no change) Yes Yes
16 UOQ T2 20 pN3a 1 pN3b IIIC (no change) Yes Yes
17 UOQ T2 5 pN2a 1 pN3b IIIA→IIIC Yes Yes
18 UIQ T1c 0 pN0 1 pN1b IA→IIA No→Yes No→Yes
Abbreviations: UOQ, upper outer quadrant; UIQ, upper inner quadrant; LIQ, lower inner quadrant; ?, radiotherapy is
controversy.
Table 5. The clinical, pathological, and treatment details of patients with positive IM‐SLN.
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8. Conclusion
Modified injection technique (two‐quadrant, high volume, and ultrasound guidance) could
significantly improve the detection rate of IM‐SLN and would promote research on IM‐SLNB.
The hypothesis of IM‐SLN lymphatic drainage pattern was demonstrated. As IMLN metastasis
is mostly concomitant with ALN metastasis, IM‐SLNB should be encouraged in clinically
positive ALN patients. IM‐SLNB should be performed routinely, for it could lead to accurate
IMLN staging and provide IM‐SLNB guided IMLN‐RT.
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